Get help now — free helplines

You can call any of these for free. You do not need a diagnosis, an appointment, or a crisis to call — questions and plain exhaustion are reasons enough.

  • Alzheimer's Association 24/7 Helpline 800-272-3900 24 hours a day, 365 days a year Free, confidential support and information for people with dementia, caregivers, families and the public. Master's-level clinicians. Also Spanish.
  • 988 Suicide & Crisis Lifeline 988 24/7 Call or text 988, or chat at 988lifeline.org. For anyone in emotional distress or a mental-health crisis, including caregivers.
  • Alzheimer's Foundation of America (AFA) Helpline 866-232-8484 9:00 am - 9:00 pm ET, seven days a week Licensed social workers providing support, info and referrals. Also text message and web chat. Text: 646-586-5283

In a medical emergency, call 911. More numbers, and what each line does, on the help page.

Find studies

A note on reading research. One study is rarely the final word.

We try to note the size of a study, whether it was in humans or animals, and how early-stage the finding is. If a summary here doesn't make that clear, treat it with extra caution and check the original source.

Increasing crystallised intelligence and fruit and vegetable consumption and eliminating depression and diabetes are likely to have the biggest impact on reducing the incidence of dementia, outweighing even the effect of removing the principal known genetic risk factor. 2 key findings →

Design: cohort study Participants: 1,433 Evidence: moderate

Depression, anxiety, and apathy symptoms are highly prevalent across dementia stages. 2 key findings →

Design: meta-analysis Participants: 5,897 Evidence: high

Brain clocks, which quantify discrepancies between brain age and chronological age, hold promise for understanding brain health and disease. 4 key findings →

Participants: 5,306 Evidence: low

Dementia diagnosis recording in general hospitals is increasing but remains less likely in some groups. 1 key finding →

Design: cohort study Participants: 21,387 Evidence: moderate

Validation of a polygenic risk score for dementia in black and white individuals

✓ Peer-reviewed alzhub usefulness score 70 out of 100. Brain and behavior 2014-07-18

Non-Hispanic white and NHB Health and Retirement Study (HRS) participants provided genetic information and either a composite memory score (n = 10,401) or a dementia probability score (n = 7690). 1 key finding →

Design: meta-analysis Participants: 10,401 Evidence: high

We found no significant association for exposure to nitrogen oxides (five studies, n=241 409, pooled adjusted HR per 10 μg/m 3 increase, 1·05 [0·97-1·13]; I 2 =44%), PM 10 (four studies, n=246 440, pooled adjusted HR per 15 μg/m 3 increase, 1·52 [0·80-2·87]; I 2 =82%), or annual ozone (four studies, n=419 972, pooled adjusted HR per 45 μg/m 3 increase, 0·82 [0·35-1·92]; I 2 =69%), with moderate to considerable heterogeneity between studies in these pooled analyses. 5 key findings →

Design: meta-analysis Participants: 24,030,527 Evidence: moderate

Incidence and prediction of falls in dementia: a prospective study in older people

✓ Peer-reviewed alzhub usefulness score 69 out of 100. PloS one 2009-05-13

The management of symptomatic orthostatic hypotension, autonomic symptoms and depression, and the encouragement of physical activity may provide the core elements for the most fruitful strategy to reduce falls in people with dementia. 2 key findings →

Participants: 179 Evidence: high

Dual-task performances can be improved in patients with dementia: a randomized controlled trial

✓ Peer-reviewed alzhub usefulness score 69 out of 100. Neurology 2010-05-05

Classification of evidence This study provides Class II evidence that specific dual-task training improves dual-task performance during walking under complex S3 conditions in geriatric patients with mild to moderate dementia. 3 key findings →

Evidence: high

Lifestyle for Brain Health (LIBRA) may help in identifying and monitoring risk status in dementia-prevention programmes, by targeting modifiable, lifestyle-related risk factors. 2 key findings →

Design: systematic review Participants: 949 Evidence: high

Ageing of the population, together with population growth, has brought along an ample increase in the number of older individuals living with dementia and disabilities. 5 key findings →

Design: randomized controlled trial Evidence: high

When zero inflation was taken into account, between-site differences in disability scores were largely attributable to compositional differences in health and sociodemographic characteristics. 5 key findings →

Design: cross-sectional Participants: 15 Evidence: low

Random-effects models revealed small but statistically significant effects with better psychological well-being in African American caregivers compared with white caregivers in both population-based (d = -0.22) and convenience sample studies (d = -0.21). 2 key findings →

Design: meta-analysis Participants: 159 Evidence: high

Our prediction model was internally evaluated based on five-fold cross-validation on discrimination and calibration, and it was further compared with existing prediction scales. 2 key findings →

Design: longitudinal study Participants: 2,416 Evidence: moderate

Inequalities in dementia incidence between six racial and ethnic groups over 14 years

✓ Peer-reviewed alzhub usefulness score 68 out of 100. Alzheimer's & Dementia 2016-03

This large study followed over 274,000 members of a single California health system for 14 years and found striking differences in dementia rates by race and ethnicity. 5 key findings →

Design: cohort Participants: 274,283 Evidence: high

We were unable to detect a difference in HRQOL for screening for ADRD among older adults. 3 key findings →

Design: randomized controlled trial Participants: 2,008 Evidence: high

Combining modifiable risk factors and risk of dementia: a systematic review and meta-analysis

✓ Peer-reviewed alzhub usefulness score 68 out of 100. BMJ open 2019-01-25

The strength of the reported associations, the consistency across studies and the suggestion of a dose response supports a need to keep modifiable risk factor exposure to a minimum and to avoid exposure to additional modifiable risks. 3 key findings →

Design: systematic review Evidence: high

From across this tag

10 of the 1,233 studies in this tag, picked by a fixed rule (a hash of each study's address), not by score or date; each page of this list shows a different 10. The same 10 appear here every time.

↑ Change the filters

Where “Free full text” comes from

Free full text links and the Full text may need a subscription label come from Unpaywall, Europe PMC and OpenAlex records of free copies, checked 10 Oct 2026. A study with neither is unknown, not paywalled. Show only studies that are free to read

How the 0–100 score works — and why some entries are capped

This is alzhub's own score. It is not an official metric, not an impact factor, and no journal, publisher or ranking body endorses it. We built it so that a reader who is not a scientist can tell a landmark trial from a conference abstract without having to already know the difference. Every point comes from one of 20 components, all of them printed on the study itself, so you can disagree with our arithmetic rather than having to trust the total.

  • Journal tier up to 10 pts
  • Journal's citation record up to 4 pts
  • Study design up to 12 pts
  • Strength of evidence up to 5 pts
  • Peer-review validation up to 10 pts
  • How recent up to 5 pts
  • Sample size up to 4 pts
  • Effect reported up to 3 pts
  • Studied in people up to 3 pts
  • Randomised / blinded up to 2 pts
  • Times cited up to 7 pts
  • Citations per year up to 5 pts
  • Impact for its field and year up to 6 pts
  • Cited by studies here up to 6 pts
  • Still being cited up to 4 pts
  • Senior author's track record up to 4 pts
  • Institution's track record up to 3 pts
  • Multi-centre collaboration up to 3 pts
  • Indexed in PubMed up to 2 pts
  • Free to read up to 2 pts

Journals are placed in ordered tiers, never given a numeric impact factor — we could not verify current impact factors from a source we control, and an invented one would be worse than none. Tier 1 is the top-tier general journals (NEJM, The Lancet, JAMA, Nature, Science, Nature Medicine); tier 2 is the leading specialty journals; tier 3 is every other peer-reviewed journal. A separate part scores how much the journal's own papers are cited, which tells the tier-3 journals apart.

Two rules we don't bend. First, we never fill in a missing value: if a record does not state a sample size or a design, that component scores zero, and if we simply have no data for a part, such as a citation count, that part is left out and the study is scored on the parts we could check. The study card says which. Second, anything that is not a peer-reviewed article is capped at 16/100 and carries a warning chip — so a conference abstract or a company press release can never outrank a peer-reviewed paper, no matter how good it looks.

We rank a rigorous null result — a good trial showing that something does not work — above an early positive finding. Someone deciding whether to buy a supplement is served by that, and the rigour is already counted by the design and journal components.

The score is computed from the published data alone and is reproducible: the same file always yields the same numbers.

See the whole rubric drawn out → — four charts covering all 27,380 studies: how the scores are spread and where the cap bites, which of the 20 components the library is strong and weak on, which subjects rest on stronger evidence, and what kinds of study each subject is actually built from.

What this library is — and isn't

This is a large sample of the Alzheimer's literature, not an exhaustive index of it. It holds 27,380 records, built mostly from automated pulls of Europe PMC (60.6% of the library) and OpenAlex (18.6%), plus smaller pulls from PubMed, Crossref and medRxiv. If a study, a drug, or a finding isn't here, that is not evidence it doesn't exist in the literature — it may simply not have been pulled in yet.

1,032 records (3.8% of the library) are not peer-reviewed — 962 of those are preprints posted before any journal review, and the rest are conference abstracts, regulatory notices and reports. Every study card on this page states its status plainly, and the score above is capped for anything that isn't a peer-reviewed article.

See the full, machine-readable breakdown of this library's coverage →

Newest studies, as a dated timeline →    Atom feed